Open AccessAdult paroxysmal cold hemoglobinuria following mRNA COVID‐19 vaccination
Author(s) -
Misawa Kyohei,
Yasuda Hajime,
Koyama Daisuke,
Inano Tadaaki,
Inoguchi Akemi,
Shirasu Chinami,
Takano Hina,
Iwao Noriaki,
Ando Miki,
Koike Michiaki
Publication year - 2022
Publication title -
ejhaem
Language(s) - English
Resource type - Journals
ISSN - 2688-6146
DOI - 10.1002/jha2.508
Subject(s) - autoimmune hemolytic anemia , immunology , paroxysmal nocturnal hemoglobinuria , vaccination , hemolysis , hemoglobinuria , medicine , antibody , eculizumab , hemolytic anemia , complement system , virology
Paroxysmal cold hemoglobinuria (PCH) is an extremely rare subtype of autoimmune hemolytic anemia (AIHA) in adults. PCH is caused by the biphasic Donath–Landsteiner (DL) antibody which fixes complement to red blood cells at low temperatures and dissociates at warmer temperatures, leading to complement‐mediated intravascular hemolysis. Autoimmune hematological disorders including AIHA and immune thrombocytopenia have been reported to develop following the mRNA COVID‐19 vaccination. However, PCH developing subsequent to mRNA vaccination has never been reported. We report a 59‐year‐old male who developed PCH approximately a month after his second mRNA COVID‐19 vaccination.